Next-gen Duchenne drug from Entrada disappoints in study

STAT·May 7

✦ NabkaNews BriefAuto-summarized from multiple outlets · verify with the source

A study of a next-generation drug for Duchenne from Entrada has yielded disappointing results, with the drug performing below expectations. This has led to a decline in Entrada's shares. The news appears unrelated to other recent developments in the pharmaceutical industry, including the FDA's reconsideration of a previously rejected rare cancer treatment.

Full coverage

Entrada crashes as Duchenne therapy comes in ‘below expectations’ in early study

BioSpace·May 7

Entrada shares dive as Duchenne results disappoint

BioPharma Dive·May 7

Recon: FDA to reconsider Atara, Pierre Fabre drug after surprise rejection; Amazon to stock Ozempic at US kiosks

RAPS·May 7

FDA revisits a rare cancer treatment it rejected a few months ago